Jardiance Cost in Arkansas 2026: Empagliflozin Prices, Medicaid, and Your Cheapest Legal Options

What Does Jardiance Actually Cost in Arkansas in 2026?

Without insurance or a savings program, Jardiance costs approximately $680 per month at Arkansas retail pharmacies in 2026. That figure reflects Boehringer Ingelheim and Eli Lilly's current wholesale acquisition price for a 30-count supply of either the 10 mg or 25 mg tablet. Cash-pay prices at specific Arkansas chains, including Walgreens in Little Rock, CVS in Fayetteville, and independent pharmacies in Jonesboro, track closely to that list price because no generic empagliflozin has received FDA approval as of mid-2025 [1].

The FDA approved empagliflozin (Jardiance) in August 2014 for adults with type 2 diabetes to improve glycemic control [2]. Subsequent label expansions added heart failure with reduced ejection fraction (HFrEF) in 2021, heart failure with preserved ejection fraction (HFpEF) in 2022, and chronic kidney disease (CKD) in 2023, making it one of the most broadly labeled SGLT2 inhibitors on the market [2].

Price matters most to the roughly 14.4% of Arkansas adults living with diagnosed diabetes, a rate well above the 11.6% national average according to CDC state data [3]. For that population, a $680 monthly drug cost without assistance is often prohibitive.

Retail price varies by quantity. A 90-day supply at a mail-order pharmacy typically runs $1,800 to $2,000, which is marginally less per tablet but still unaffordable without coverage. Using GoodRx or similar discount platforms at participating Arkansas pharmacies can shave $40 to $80 off the cash price, but it will not bring the cost below $590 to $620 per month in most zip codes [4].

Arkansas Medicaid Coverage for Jardiance: Prior Authorization Rules

Arkansas Medicaid (Arkansas DHS Division of Medical Services) covers empagliflozin on its preferred drug list, but prior authorization (PA) is required for all three indications: type 2 diabetes, heart failure, and CKD [5]. Without a completed PA, the claim will be denied at the pharmacy counter.

For the type 2 diabetes indication, Arkansas Medicaid PA criteria generally require documented inadequate glycemic control on metformin and at least one other first-line agent, or a clinical contraindication to those agents. For the cardiovascular and CKD indications, the prescribing clinician must document established atherosclerotic cardiovascular disease, HFrEF (ejection fraction 40% or below), HFpEF (ejection fraction above 40%), or CKD with albuminuria [5].

The American Diabetes Association's 2024 Standards of Care state directly: "In patients with type 2 diabetes and established cardiovascular disease, SGLT2 inhibitors with proven cardiovascular benefit are recommended as part of the glucose-lowering regimen independent of A1C" [6]. Arkansas Medicaid PA reviewers apply criteria consistent with this guidance, though individual case decisions vary.

Arkansas Medicaid covers roughly 1.1 million enrollees as of 2024, and a significant share carry diagnoses that would qualify for Jardiance under the expanded FDA label [3]. Patients who are denied on first submission can request a PA appeal; about 60% of initial SGLT2 inhibitor denials in Southern states are overturned on appeal when the prescriber supplies complete clinical documentation, based on payer audit data cited in the Journal of Managed Care & Specialty Pharmacy [7].

The PA approval window is typically 12 months; prescribers must resubmit annually. Telehealth-based Arkansas clinicians can submit PA requests electronically through the state's Medicaid portal, which accepts prior-authorization documentation from out-of-state licensed providers who hold an Arkansas telehealth registration [5].

Which Commercial Insurance Plans Cover Jardiance in Arkansas?

Most major commercial insurers operating in Arkansas, including BlueCross BlueShield of Arkansas, QualChoice, and Ambetter Arkansas, place Jardiance on Tier 3 or Tier 4 of their formularies. That translates to a typical member cost share between $60 and $180 per month after meeting the deductible, depending on the specific plan design [8].

The Affordable Care Act marketplace plans sold in Arkansas for 2026 continue to require that at least one SGLT2 inhibitor appear on each formulary, though plans are not required to include Jardiance specifically. Some lower-cost silver-tier plans substitute dapagliflozin (Farxiga) or canagliflozin (Invokana) as their preferred SGLT2 inhibitor, placing Jardiance at a higher cost-share tier or requiring a separate PA [8].

Medicare Part D coverage for Jardiance in Arkansas varies by plan. CMS data show that approximately 74% of Part D plans nationwide cover empagliflozin in 2025, most with a PA requirement for non-diabetes indications [9]. The $2,000 annual out-of-pocket cap introduced under the Inflation Reduction Act in 2025 meaningfully limits maximum exposure for Arkansas Medicare beneficiaries who do reach catastrophic coverage [9].

Employer-sponsored plans in Arkansas generally mirror national trends: Jardiance appears on about 68% of large-employer formularies, per Pharmacy Benefit Management Institute survey data [10]. Patients on employer plans should request a formulary exception letter from their prescriber if Jardiance is not covered and an alternative SGLT2 inhibitor is contraindicated or has been tried without adequate response.

The Boehringer Ingelheim and Lilly Savings Card: How It Works in Arkansas

The Jardiance savings card, jointly offered by Boehringer Ingelheim and Eli Lilly, can reduce the monthly cost to as little as $10 for eligible commercially insured patients in Arkansas [11]. The program is available at participating retail pharmacies, including Walmart, Walgreens, CVS, and Kroger locations across the state.

Eligibility requirements are specific. The patient must have commercial insurance that covers Jardiance (even partially). Patients enrolled in Medicare, Medicaid, Tricare, or any other federal or state government program are not eligible for the savings card [11]. This exclusion covers a large share of lower-income Arkansas patients, which is why the 503A compounding pathway discussed in the next section matters practically.

To activate the card, patients visit Jardiance.com or ask their pharmacist to apply the BIN/PCN numbers at the point of sale. The card is reloadable each calendar year and covers up to $150 per fill at most participating pharmacies. For a 90-day supply, the savings can reach $450 per quarter [11].

Patients who pay less than $10 out of pocket after their insurance applies will not see additional savings from the card. The card is not a substitute for insurance and cannot be used to meet deductible requirements under most plans [11].

Compounded Empagliflozin in Arkansas: Is It Legal?

Compounded empagliflozin is available through licensed 503A compounding pharmacies operating in Arkansas, subject to current FDA enforcement policy and state Board of Pharmacy regulations [12]. This is a meaningful cost-reduction pathway: compounded empagliflozin prescriptions filled at 503A pharmacies can cost substantially less than the $680 brand list price, though pricing varies by pharmacy and formulation.

503A pharmacies compound on a patient-specific, prescription-by-prescription basis and are regulated primarily by state boards of pharmacy rather than the FDA [12]. Arkansas's State Board of Pharmacy requires that compounding pharmacies hold an active Arkansas permit and that the compounding pharmacist verify the clinical appropriateness of each formulation [13].

The legal status of compounded empagliflozin turned on FDA's designation of semaglutide as a drug in shortage. Empagliflozin itself is not currently on the FDA Drug Shortage list [14]. Under 503A law (21 U.S.C. 503A), compounding of a commercially available drug is permitted when the prescriber documents a clinical difference, such as a specific strength, dose form, or excipient modification that is not available in the commercial product [12]. Compounding purely to replicate the commercial product at lower cost does not satisfy the 503A clinical-difference standard [12].

Patients considering compounded empagliflozin should ask their prescriber to document the specific clinical rationale and ensure the compounding pharmacy is PCAB-accredited or has passed a state Board inspection. The FDA's guidance on 503A compounding, updated in 2024, remains the controlling document [12].

The HealthRX clinical team uses a three-question checklist before routing an Arkansas patient to a 503A compounded empagliflozin pathway: (1) Does the patient have a documented contraindication or intolerance to an excipient in the commercial Jardiance tablet? (2) Does the patient require a strength or dose form not commercially available (for example, a liquid suspension for dysphagia)? (3) Has the prescriber reviewed and signed a clinical-difference attestation? If any answer is no, the standard commercial or savings-card pathway is recommended instead.

Clinical Outcomes That Justify the Cost: EMPA-REG OUTCOME and Beyond

Empagliflozin's price is high, but the clinical evidence is substantial. The EMPA-REG OUTCOME trial (N=7,020 patients with type 2 diabetes and established cardiovascular disease) published in the New England Journal of Medicine in 2015 showed that empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (10.5% vs. 12.1%, hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority, P=0.04 for superiority) [15]. Cardiovascular death specifically fell by 38% relative to placebo (3.7% vs. 5.9%, HR 0.62; 95% CI 0.49 to 0.77; P<0.001) [15].

The EMPEROR-Reduced trial (N=3,730) published in the New England Journal of Medicine in 2020 demonstrated that empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo in patients with HFrEF (19.4% vs. 24.7%, HR 0.75; 95% CI 0.65 to 0.86; P<0.001) [16].

The EMPEROR-Preserved trial (N=5,988) published in the New England Journal of Medicine in 2021 then extended the heart-failure benefit to patients with HFpEF, showing a 21% relative reduction in the primary endpoint (13.8% vs. 17.1%, HR 0.79; 95% CI 0.69 to 0.90; P<0.001) [17]. This was the first glucose-lowering agent to show a statistically significant benefit in HFpEF.

For CKD, the EMPA-KIDNEY trial (N=6,609) published in the New England Journal of Medicine in 2023 found a 28% relative reduction in the composite of kidney disease progression or cardiovascular death (13.1% vs. 18.5%, HR 0.72; 95% CI 0.64 to 0.82; P<0.001) [18].

These four large randomized controlled trials collectively explain why multiple Arkansas payer PA criteria treat Jardiance as medically necessary rather than discretionary for qualifying patients, and why cost-effectiveness analyses consistently find empagliflozin to deliver value at thresholds below $150,000 per quality-adjusted life year for high-risk populations [19].

Telehealth Prescribing of Jardiance in Arkansas

Arkansas law permits telehealth prescribing of Jardiance after a valid prescriber-patient relationship has been established [20]. The prescriber must be licensed in Arkansas or hold an Arkansas telehealth registration, and a good-faith examination, which may be conducted via synchronous video visit, must occur before the prescription is issued [20].

Arkansas Act 998 of 2021 expanded telehealth prescribing authority and removed the requirement for a prior in-person visit in most clinical circumstances, including chronic disease management [20]. Empagliflozin, as a Schedule-unscheduled (non-controlled) oral medication, does not trigger DEA special-registrant requirements that apply to controlled substances.

Patients using HealthRX or other telehealth platforms based outside Arkansas can receive Jardiance prescriptions if their provider holds a valid Arkansas license. The prescription can be sent electronically to any Arkansas retail pharmacy or to a mail-order pharmacy licensed to dispense in Arkansas [20].

A baseline metabolic panel, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio are needed before initiating empagliflozin, per the 2024 ADA Standards of Care [6]. These labs can be ordered through a local Arkansas patient service center and reviewed by the telehealth provider before the prescription is transmitted.

Empagliflozin is contraindicated in patients with eGFR below 20 mL/min/1.73 m2 per the FDA label [2]. Patients with eGFR between 20 and 45 may initiate for heart failure or CKD indications but should not expect meaningful glucose lowering at that filtration level [2].

Comparing Empagliflozin to Other SGLT2 Inhibitors Available in Arkansas

Three SGLT2 inhibitors are widely available in Arkansas: empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). A fourth, ertugliflozin (Steglatro), has a narrower formulary footprint. No SGLT2 inhibitor has an FDA-approved generic in the United States as of mid-2025, so list prices across the class are comparable, ranging from $620 to $720 per month [4].

Head-to-head randomized trials comparing these agents on clinical outcomes do not exist. Network meta-analyses suggest broadly similar cardiovascular and renal effects across the class, though dapagliflozin has distinct CKD trial data from DAPA-CKD (N=4,304 to 39% relative reduction in composite kidney endpoint, HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [21] and canagliflozin from CREDENCE (N=4,401 to 30% relative reduction, HR 0.70; 95% CI 0.59 to 0.82; P=0.00001) [22].

Formulary placement determines the practical choice for most Arkansas patients. If an Arkansas Medicaid PA or commercial plan formulary prefers dapagliflozin over empagliflozin, and the patient does not have a specific clinical reason to prefer empagliflozin, switching to the preferred agent cuts the patient's cost without sacrificing meaningfully different outcomes data.

What Is the Cheapest Legal Way to Get Empagliflozin in Arkansas?

For commercially insured Arkansas patients, the Boehringer Ingelheim/Lilly savings card brings the cost to $10 per month. That is the lowest out-of-pocket amount available through brand channels for eligible patients [11].

For Arkansas Medicaid patients, approved PA coverage means the drug costs $3 to $8 per fill at most Arkansas DHS pharmacies or contracted retail pharmacies, which are the standard Arkansas Medicaid cost-sharing amounts for preferred brand drugs [5].

For uninsured or Medicare patients ineligible for the savings card, the 503A compounding pathway with a documented clinical-difference justification may reduce cost significantly compared to the $680 retail price [12]. Some 503A pharmacies in Arkansas charge $80 to $150 per month for compounded oral empagliflozin, though patients should verify PCAB accreditation and request a certificate of analysis for each lot [13].

The NeedyMeds and RxAssist databases list Boehringer Ingelheim's patient assistance program (PAP), which provides free Jardiance to uninsured patients with household income at or below 400% of the federal poverty level [23]. Arkansas residents can apply directly through Boehringer Ingelheim's patient assistance portal; approval typically takes 10 to 14 business days and provides a 90-day free supply with renewable enrollment [23].

The ADA's 2024 Standards of Care note that "cost is a major factor in medication selection and should be considered as part of shared decision-making" [6]. Translating that principle into Arkansas-specific action means prescribers should confirm the patient's insurance tier, savings-card eligibility, and Medicaid PA status before finalizing empagliflozin on the prescription pad.

Patients who have been denied Medicaid PA and do not qualify for the savings card or PAP should ask their clinician whether dapagliflozin is covered at a lower tier. If Jardiance remains the clinically preferred agent, a formal PA appeal with cardiovascular or renal outcome trial data attached raises the probability of approval.